Frank Manganella
Corporate Officer/Principal bij NEXIEN BIOPHARMA, INC.
Profiel
Frank Manganella is the founder and CEO of CH3 Partners LLC, which was founded in 2015.
He is also the founder of Ch3 Ventures.
Currently, he holds the position of Vice President-Corporate Development at Nexien BioPharma, Inc. since 2018 and the position of Chief Financial Officer & Managing Partner at CRx Bio Holdings LLC since 2017.
In the past, he worked as Managing Director & Head-FICC Sales at Commerzbank AG from 2011 to 2014.
Mr. Manganella received an MBA from Durham University Business School in 2013.
Actieve functies van Frank Manganella
| Bedrijven | Functie | Begin |
|---|---|---|
| NEXIEN BIOPHARMA, INC. | Corporate Officer/Principal | 30-10-2018 |
| CH3 Partners LLC | Algemeen Directeur | 01-10-2015 |
CRx Bio Holdings LLC
 CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Financieel Directeur/CFO | 01-11-2017 |
| Ch3 Ventures | Oprichter | - |
Eerdere bekende functies van Frank Manganella
| Bedrijven | Functie | Einde |
|---|---|---|
| COMMERZBANK AG | Corporate Officer/Principal | 01-06-2014 |
Opleiding van Frank Manganella
| Durham University Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| COMMERZBANK AG | Finance |
| NEXIEN BIOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
CRx Bio Holdings LLC
CRx Bio Holdings LLC Pharmaceuticals: OtherHealth Technology CRx Bio Holdings LLC engages in the research and development of advanced cannabinoid therapeutic formulations with the objective of enhancing the bioavailability, pharmacokinetics, and pharmacodynamics of cannabinoids. The company was founded by Alex Wasyl and is headquartered in Princeton, NJ. | Health Technology |
| CH3 Partners LLC | |
| Ch3 Ventures |
